Sodium-glucose cotransporter-2 (SGLT2) inhibitors, initially developed for type 2 diabetes management, have demonstrated remarkable cardiovascular and renal benefits beyond glycemic control [5]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.